Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 975

Sort by

Sort Order Select

Journal Articles

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Blood (2021) 138 (4): 331–343.

https://doi.org/10.1182/blood.2020010438

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma

David D. W. Twa, Derrick G. Lee, King L. Tan, Graham W. Slack, Susana Ben-Neriah, Diego Villa, Joseph M. Connors, Laurie H. Sehn, Anja Mottok, Randy D. Gascoyne, David W. Scott, Christian Steidl, Kerry J. Savage

Blood (2021) 137 (9): 1256–1259.

https://doi.org/10.1182/blood.2020006338

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Thomas A. Ollila, Habibe Kurt, Jozal Waroich, John Vatkevich, Ashlee Sturtevant, Nimesh R. Patel, Patrycja M. Dubielecka, Diana O. Treaba, Adam J. Olszewski

Blood (2021) 137 (8): 1120–1124.

https://doi.org/10.1182/blood.2020007236

Published: 2021

Includes: Supplemental data

Journal Articles

Pediatric hemophagocytic lymphohistiocytosis

Scott W. Canna, Rebecca A. Marsh

Blood (2020) 135 (16): 1332–1343.

https://doi.org/10.1182/blood.2019000936

Published: 2020

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Julie Kanter, MD, Mary Dooley, MS, Logan P Sirline, MPH, Martina Mueller, PhD, Shannon Phillips, PhD RN, Alyssa M Schlenz, PhD, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS

Blood (2019) 134 (Supplement_1): 2270.

https://doi.org/10.1182/blood-2019-129951

Published: 2019

Journal Articles

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Adam Zayac, MD, Andrew Matthew Evens, DO,MMSc, Andrzej Stadnik, MPH, BS, Stephen D. Smith, MD, Deepa Jagadeesh, MDMPH, Lori A. Leslie, MD, Catherine Wei, MD MA, Seo-Hyun Kim, MD, Seema Naik, MD, Suchitra Sundaram, MD, Nishitha Reddy, MD, Umar Farooq, MD, Vaishalee P. Kenkre, MD, Narendranath Epperla, MDMS, Kristie A. Blum, MD, Nadia Khan, MD, Daulath Singh, MD, Juan Pablo Alderuccio, MD, Amandeep Godara, MD, Maryam Yazdy, MD, Catherine Diefenbach, MD, Emma Rabinovich, MD, Gaurav Varma, MDMPH, Reem Karmali, MD, Yusra Shao, MD, Asaad Trabolsi, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Sarah Stettner, Ayushi Chauhan, MBBS, Yun Kyong Choi, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Michael C. Churnetski, Kirsten M Boughan, DO, Stephanie Berg, DO, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Christopher D'Angelo, MD, David A. Bond, MD, Seth M Maliske, MD, Ryan Vaca, MD, Gabriela Magarelli, APN, Amy Sperling, BS, Max J. Gordon, MD, Kevin A. David, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Parameswaran Venugopal, MD, Izidore S. Lossos, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 402.

https://doi.org/10.1182/blood-2019-122990

Published: 2019

Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD

Blood (2019) 134 (Supplement_1): 2319.

https://doi.org/10.1182/blood-2019-126342

Published: 2019

Journal Articles

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Sangeetha Gandhi, MBBS, N. Nora Bennani, MD, Sonia Fortin, Thomas M. Habermann, MD, Patrick Johnston, MD, James R. Cerhan, MD PhD, Kay M. Ristow, BS, Carrie A. Thompson, MD, Grzegorz Nowakowski, MD, Yi Lin, MD PhD, Jose C Villasboas, MD, Luis Porrata, MD, Thomas E. Witzig, MD, Ivana Micallef, MD, David J Inwards, MD, Stephen M Ansell, MD PhD, Jonas Paludo, MD

Blood (2019) 134 (Supplement_1): 5293.

https://doi.org/10.1182/blood-2019-131965

Published: 2019

Journal Articles

A Comprehensive Study of Human Integrins in Pediatric Lymphoblastic Leukemia Supports a Role of CD49f (Integrin α6) in the Localization to Bone Marrow but Not Spinal Fluid

Bibi F. S. S. Scharff, Signe Modvig, MD PhD, Maria Thastrup, PhD, Mette Levinsen, PhD, Matilda Degn, PhD, Lars Peter Ryder, MSc, Kjeld Schmiegelow, Professor MD DMSc., Claus René Lykke Christensen, MSc, MSc.Eng, PhD, Hanne Vibeke Marquart, MD PhD

Blood (2019) 134 (Supplement_1): 5205.

https://doi.org/10.1182/blood-2019-126701

Published: 2019

Journal Articles

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Susan Prockop, MD, Minoti Hiremath, MBBS, PhD, Wei Ye, PhD, Laurence Gamelin, MD, Willis Navarro, MD, Kris Michael Mahadeo, MD

Blood (2019) 134 (Supplement_1): 5326.

https://doi.org/10.1182/blood-2019-129277

Published: 2019

Journal Articles

PD-L1 Expression in Patients with Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Its Correlation with Serum Levels of Soluble Programmed Death-Ligand 1 (sPD-L1)

Inju Cho, MD PhD, Seok Jin Kim, MD PhD, Hansang Lee, MD, Young Hyeh Ko, MD

Blood (2019) 134 (Supplement_1): 1601.

https://doi.org/10.1182/blood-2019-123311

Published: 2019

Journal Articles

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

Geoffrey L. Uy, MD, Jun Yin, PhD, Heidi D. Klepin, MD, Shira Dinner, MD, Anthony J. Jaslowski, MD, Stephen A. Strickland, MD, Jane L. Liesveld, MD, John C. Byrd, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 1366.

https://doi.org/10.1182/blood-2019-127142

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Bryan Hambley, MD, Eric Gehrie, Jonathan Webster, MD, Margaret M. Showel, MD, Lukasz P. Gondek, MD PhD, William Brian Dalton, MD PhD, Gabrielle T. Prince, MD, Douglas E Gladstone, MD, Ivana Gojo, MD, Gabriel Ghiaur, MD PhD, Keith W. Pratz, MD, B. Douglas Smith, MD, Amy E. DeZern, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 3841.

https://doi.org/10.1182/blood-2019-123229

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Shilpa Paul, PharmD, Koji Sasaki, MD, J Michael Savoy, PharmD, Adam Dipippo, PharmD, Nadya Jammal, PharmD, Kayleigh Marx, PharmD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3810.

https://doi.org/10.1182/blood-2019-130284

Published: 2019

Journal Articles

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Meera Yogarajah, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Dong Chen, MD PhD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Michelle A Elliott, MD, Mark Litzow, MD, Aref Al-Kali, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Kebede H. Begna, MD

Blood (2019) 134 (Supplement_1): 3863.

https://doi.org/10.1182/blood-2019-125361

Published: 2019

Journal Articles

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Harinder Gill, FRCP, FRCPath, Rita Yim, PhD, Cyrus R Kumana, FRCP, Yok-Lam Kwong, MD

Blood (2019) 134 (Supplement_1): 3853.

https://doi.org/10.1182/blood-2019-125185

Published: 2019

Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 4084.

https://doi.org/10.1182/blood-2019-123772

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Pediatric hemophagocytic lymphohistiocytosis

Erdheim-Chester disease

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

A Comprehensive Study of Human Integrins in Pediatric Lymphoblastic Leukemia Supports a Role of CD49f (Integrin α6) in the Localization to Bone Marrow but Not Spinal Fluid

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

PD-L1 Expression in Patients with Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Its Correlation with Serum Levels of Soluble Programmed Death-Ligand 1 (sPD-L1)

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only